acute lymphoblastic leukaemia
News/ News/ News/ Oncology/ R&D
Takeda’s Iclusig bests imatinib in first-line leukaemia trial
Phil Taylor
acute lymphoblastic leukaemia, Iclusig, Novartis, Oncology, Takeda
0 Comment
News/ News/ News/ Oncology/ Sales and Marketing
Gilead claims first CAR-T approval for leukaemia in older adults
Phil Taylor
acute lymphoblastic leukaemia, Gilead Sciences, immuno-oncology, Kite Pharma, Kymriah, Novartis, Oncology, regulatory approval, Tecartus
0 Comment
Blackstone revs up Autolus’ CAR with $250m fuel injection
Phil Taylor
acute lymphoblastic leukaemia, Autolus, Blackstone, CAR-T therapies, cell therapy, financing, immuno-oncology, Oncology
0 Comment
Kite claims a first for CAR-T Tecartus in adult leukaemia
Phil Taylor
acute lymphoblastic leukaemia, Gilead Sciences, immuno-oncology, Kite Pharma, Kymriah, Novartis, Oncology, regulatory approval, Tecartus
0 Comment
ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data
Phil Taylor
acute lymphoblastic leukaemia, ASCO 2021, CAR-T therapies, Gilead Sciences, Kite Pharma, Kymriah, Novartis, Oncology, Tecartus
0 Comment
News/ News/ News/ Oncology/ Patients
Real-world data backs Kymriah’s safety profile, says Novartis
Phil Taylor
acute lymphoblastic leukaemia, Haematology, Kymriah, Non-Hodgkins Lymphoma, Novartis, real world data
0 Comment
Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPO
Richard Staines
acute lymphoblastic leukaemia, blood cancer, cancer, CAR T, non-Hodgkin lymphoma, R&D
0 Comment
News/ News/ Oncology/ Top stories
Amgen’s blood cancer drug gets full EU licence
Richard Staines
acute lymphoblastic leukaemia, Amgen, blood cancer
0 Comment
FDA granted full licence last year